Compare Stocks → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:SLS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeSLSSELLAS Life Sciences Group$1.41+3.7%$1.10$0.50▼$1.91$76.52M2.351.63 million shs560,811 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceSLSSELLAS Life Sciences Group+3.68%+1.44%+34.29%+177.01%-11.88%AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationSLSSELLAS Life Sciences Group0.709 of 5 stars3.52.00.00.01.10.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceSLSSELLAS Life Sciences Group3.00Buy$3.00112.77% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookSLSSELLAS Life Sciences Group$1M79.34N/AN/A($0.25) per share-5.64Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateSLSSELLAS Life Sciences Group-$37.34M-$1.36N/A∞N/AN/A-2,405.54%-241.00%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthSLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioSLSSELLAS Life Sciences GroupN/A0.230.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipSLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipSLSSELLAS Life Sciences Group1.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableSLSSELLAS Life Sciences Group1756.27 million55.37 millionNot OptionableJUP, JFJ, TFIF, and SLS HeadlinesSourceHeadlineSeligman Launches a New Health Care Fundinstitutionalinvestor.com - March 28 at 7:32 PMSELLAS Life Sciences Group files for $200M mixed shelfmsn.com - March 28 at 7:32 PMSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - March 28 at 4:05 PMBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financialsmarkets.businessinsider.com - March 27 at 10:54 PMSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Studymarkets.businessinsider.com - March 26 at 10:33 AMSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Studyglobenewswire.com - March 26 at 7:35 AMSELLAS Life Sciences Group Inc.wsj.com - March 21 at 3:15 PMSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 19 at 4:05 PMSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETglobenewswire.com - March 19 at 8:47 AMSellas Life Sciences Shares Drop 31% After Direct Offering Pricesmarketwatch.com - March 16 at 2:16 PMGeron, Graphite Bio, Immuneering among healthcare moversmsn.com - March 15 at 10:20 AMSELLAS Life Sciences looks to raise $20M in a direct offeringmsn.com - March 15 at 10:20 AMSellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placementmarkets.businessinsider.com - March 15 at 10:20 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - March 15 at 9:14 AMSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 15 at 9:00 AMAadi Bioscience Q4 2023 Earnings Previewseekingalpha.com - March 12 at 12:49 PMSellas Life Sciences Group Inc (SLS)investing.com - March 10 at 5:06 AMSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsfinanznachrichten.de - March 9 at 3:43 PMSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnershipsglobenewswire.com - March 8 at 8:00 AMSLS Mar 2024 4.000 putfinance.yahoo.com - March 7 at 11:22 PMSELLAS Life Sciences Group, Inc. (SLS)finance.yahoo.com - March 1 at 3:52 PMSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conferenceglobenewswire.com - March 1 at 8:30 AMSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Timeglobenewswire.com - February 29 at 8:00 AMSELLAS Life Sciences Group Incmorningstar.com - February 22 at 1:53 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsSELLAS Life Sciences GroupNASDAQ:SLSSELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.